JPWO2020081941A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020081941A5 JPWO2020081941A5 JP2021521130A JP2021521130A JPWO2020081941A5 JP WO2020081941 A5 JPWO2020081941 A5 JP WO2020081941A5 JP 2021521130 A JP2021521130 A JP 2021521130A JP 2021521130 A JP2021521130 A JP 2021521130A JP WO2020081941 A5 JPWO2020081941 A5 JP WO2020081941A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition
- ibudilast
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 claims 13
- 229960002491 ibudilast Drugs 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 5
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 239000011325 microbead Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862748148P | 2018-10-19 | 2018-10-19 | |
US62/748,148 | 2018-10-19 | ||
PCT/US2019/056948 WO2020081941A1 (en) | 2018-10-19 | 2019-10-18 | Methods of treating ophthalmic disease/disorder or injury with ibudilast |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022505184A JP2022505184A (en) | 2022-01-14 |
JPWO2020081941A5 true JPWO2020081941A5 (en) | 2022-10-11 |
JP7430719B2 JP7430719B2 (en) | 2024-02-13 |
Family
ID=68503211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021521130A Active JP7430719B2 (en) | 2018-10-19 | 2019-10-18 | Methods of treating eye diseases/disorders or injuries using ibudilast |
Country Status (6)
Country | Link |
---|---|
US (1) | US11154540B2 (en) |
EP (1) | EP3866788B1 (en) |
JP (1) | JP7430719B2 (en) |
CN (1) | CN112804999B (en) |
CA (1) | CA3116577A1 (en) |
WO (1) | WO2020081941A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4828003B2 (en) | 1998-08-10 | 2011-11-30 | 杏林製薬株式会社 | Drugs for multiple sclerosis |
CA2587791C (en) | 2004-12-06 | 2012-03-13 | Avigen, Inc. | Method for treating neuropathic pain and associated syndromes |
CN101355876B (en) * | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | Compositions for the eye adminstration |
US20100233194A1 (en) * | 2007-03-30 | 2010-09-16 | Jean-Philippe Combal | Treatment of neovascular ocular disease states |
US8138201B2 (en) | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
WO2013129315A1 (en) * | 2012-02-27 | 2013-09-06 | ロート製薬株式会社 | Prophylactic, ameliorating or therapeutic agent for retinal diseases |
TW201406707A (en) * | 2012-05-04 | 2014-02-16 | Acucela Inc | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases |
US10258611B2 (en) | 2014-11-26 | 2019-04-16 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
-
2019
- 2019-10-18 WO PCT/US2019/056948 patent/WO2020081941A1/en unknown
- 2019-10-18 JP JP2021521130A patent/JP7430719B2/en active Active
- 2019-10-18 EP EP19801446.6A patent/EP3866788B1/en active Active
- 2019-10-18 CA CA3116577A patent/CA3116577A1/en active Pending
- 2019-10-18 US US16/657,276 patent/US11154540B2/en active Active
- 2019-10-18 CN CN201980066306.8A patent/CN112804999B/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6445637B2 (en) | Tapentadol for preventing and treating depression and anxiety | |
JP7368859B2 (en) | Treatment of nervous system disorders using a combination of RXR agonists and thyroid hormones | |
JP6938465B2 (en) | Combination of cannabinoids and N-acylethanolamine | |
JP2017200927A (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
KR20190057324A (en) | Pharmaceutical compositions for the treatment of blepharitis | |
JP6196041B2 (en) | Methods for providing weight loss therapy in patients with major depression | |
JP2019524850A5 (en) | ||
CN113924098A (en) | Methods for treating mental disorders, behavioral disorders, cognitive disorders | |
JP2007517049A (en) | Compositions and methods for treating recurrent conditions | |
JP4746714B2 (en) | Pharmaceutical composition for treating fibromyalgia | |
CN111093772B (en) | Treatment of migraine | |
JPWO2020081941A5 (en) | ||
IE851848L (en) | Propiophenone compound against sexual dysfunction | |
Valtonen | A comparative short-term trial with Voltaren (diclofenac sodium) and naproxen in soft-tissue rheumatism | |
Muraleedharan et al. | Ayurvedic Treatment Protocol for Chronic Pelvic Pain in Endometriosis | |
WO2020207398A1 (en) | Use of ginkgo terpene lactone in preparing drug for preventing and/or treating guillain-barré-strohl syndrome | |
Gunarathna et al. | Effect of Panchatikta Ghrita and Gandhakadi Taila in the Management of Kitibha (Psoriasis)-A Case study | |
IL230174A (en) | Pharmaceutical composition for treating premature ejaculation | |
RU2796295C2 (en) | Carbamate compound and the use of a composition containing it for the prevention, relief or treatment of acute stress disorder or post-traumatic stress disorder | |
JP7408643B2 (en) | Use of carbamate compounds and preparations containing the same for the prevention, alleviation or treatment of acute stress disorder or post-traumatic stress disorder | |
Tsokolas et al. | Tolperisone, a centrally-acting muscle relaxant: a possible cause of macular haemorrhage | |
Singh et al. | A CLINICAL COMPARATIVE STUDY OF SOME VISHAGHNA DRAVAYA AND ERAND TAIL IN THE MANAGEMENT OF AMAVATA | |
WO2008041751A1 (en) | Pharmaceutical preparation for treating fibromyalgia | |
US20190038624A1 (en) | Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy | |
TW202120116A (en) | Therapeutic agent or prophylactic agent for fibromyalgia |